Press releases
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 13.90m |
Free float | 13.74m |
P/E (TTM) | -- |
Market cap | 5.11m USD |
EPS (TTM) | -4.87 USD |
Data delayed at least 20 minutes.
More ▼